Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

121. Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching

Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V, Roundtree A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V, Roundtree A. Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Report No 86. 2007 Authors' objectives The objectives of this report were to review the available data on the treatment of Rheumatoid Arthritis (RA

Health Technology Assessment (HTA) Database.2007

122. Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness

Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Moffett M, Pak C, Skidmore B, Kimmel B, Kallen (...) M, Cox V Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Moffett M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V. Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs

Health Technology Assessment (HTA) Database.2007

123. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill R A, Jones A, Mujica Mota R, Walley T CRD summary (...) This review, which assessed the clinical effectiveness of anti-tumour necrosis factor-α therapy for patients with ankylosing spondylitis, concluded that the therapy is clinically effective in the short term. The authors' conclusions are likely to be reliable. Authors' objectives To assess the comparative clinical effectiveness and cost-effectiveness of anti-tumour necrosis factor (TNF)-α therapy (adalimumab, etanercept and infliximab) for the treatment of ankylosing spondylitis. This abstract will only

DARE.2007

124. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2006

125. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation

NIHR HTA programme2006

126. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R CRD summary (...) This review concluded that there was some evidence, from three trials, to suggest that both etanercept and infliximab are efficacious treatments for psoriatic arthritis. Short-term benefits for joint and psoriasis symptoms and functional status were observed with both drugs, but further research is needed to assess the long-term benefits. The review was well conducted and its conclusions are likely to be reliable. Authors' objectives To assess the clinical effectiveness, safety, tolerability and cost

DARE.2006

127. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) arthritis in adults and an economic evaluation of their cost-effectiveness Chen Y F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A CRD summary This review concluded that adalimumab, etanercept and infliximab are effective treatments compared with placebo for patients with rheumatoid arthritis who are not well-controlled by disease-modifying antirheumatic drugs. Combination with methotrexate seems more effective in early rheumatoid arthritis. An increased risk of infection may

DARE.2006

128. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation

Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, Wells G A Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, Wells G A. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report Issue 64. 2006 Authors' objectives The aim of this report is to provide a clinical review and economic

Health Technology Assessment (HTA) Database.2006

129. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Boonen A, van der Heijde D, Severens J L (...) , Boendermaker A, Landewe R, Braun J, Brandt J, Sieper J, van der Linden S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Etanercept (25 mg twice weekly) and infliximab (5 mg/kg every 6 weeks after the usual loading dose at weeks 0, 2

NHS Economic Evaluation Database.2006

130. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) , etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006; 10(42): 1-248 Authors' objectives This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-a (TNF-a), when used in the treatment of rheumatoid arthritis (RA) in adults. Authors' conclusions Adalimumab, etanercept and infliximab are effective

Health Technology Assessment (HTA) Database.2006

131. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31): 1-258 Authors' objectives

Health Technology Assessment (HTA) Database.2006

132. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis

Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No.79. 2006 Authors' objectives The aim of this report was to assess the use of etanercept, infliximab and adalimumab

Health Technology Assessment (HTA) Database.2006

133. Etanercept and infliximab for the treatment of adults with psoriatic arthritis

Etanercept and infliximab for the treatment of adults with psoriatic arthritis Etanercept and infliximab for the treatment of adults with psoriatic arthritis Etanercept and infliximab for the treatment of adults with psoriatic arthritis National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute (...) for Health and Clinical Excellence. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 102. 2006 Authors' objectives The aim of this review is to provide guidance on the use of etanercept and infliximab for the treatment of adults with psoriatic arthritis. Authors' conclusions 1 Guidance 1.1 Etanercept, within its licensed indications, is recommended for the treatment of adults

Health Technology Assessment (HTA) Database.2006

134. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. 16226614 2005 10 17 2005 11 08 2015 11 19 1474-547X 366 9494 2005 Oct 15-21 Lancet (London, England) Lancet Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. 1367-74 Tumour necrosis factor alpha (TNFalpha) is thought to play a part in the pathogenesis of psoriasis. We assessed the efficacy (...) and safety of continuous treatment with infliximab, a monoclonal antibody that binds to and neutralises the activity of TNFalpha, in patients with psoriasis. In this phase III, multicentre, double-blind trial, 378 patients with moderate-to-severe plaque psoriasis were allocated in a 4:1 ratio to receive infusions of either infliximab 5 mg/kg or placebo at weeks 0, 2, and 6, then every 8 weeks to week 46. At week 24, placebo-treated patients crossed over to infliximab treatment. Skin and nail signs

Lancet2005

135. Infliximab (Remicade) for ulcerative colitis - horizon scanning review

Infliximab (Remicade) for ulcerative colitis - horizon scanning review Infliximab (Remicade) for ulcerative colitis - horizon scanning review Infliximab (Remicade) for ulcerative colitis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Infliximab (Remicade) for ulcerative colitis - horizon scanning (...) review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to summarise the currently available evidence on Infliximab (Remicade) for ulcerative colitis. Authors' conclusions Infliximab (Remicade), an anti-tumor necrosis factor (TNF) agent, is in development for the treatment of active ulcerative colitis (UC). Two phase III trials (364 patients in each) that reported at conference in May 2005, demonstrated that infliximab met its primary and secondary

Health Technology Assessment (HTA) Database.2005

136. A home infliximab infusion program

A home infliximab infusion program A home infliximab infusion program A home infliximab infusion program Condino A A, Fidanza S, Hoffenberg E J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the home-based (...) treatment of paediatric inflammatory bowel disease (PIBS) using an infliximab infusion. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients were selected for the intervention if they were compliant with hospital-based infliximab infusions and other medications, had no adverse events when receiving hospital-based infliximab infusions, were in remission, and had access to experienced paediatric homecare nursing. Setting The intervention took place

NHS Economic Evaluation Database.2005

137. The cost-effectiveness of infliximab for severe treatment resistant rheumatoid arthritis in the UK

The cost-effectiveness of infliximab for severe treatment resistant rheumatoid arthritis in the UK The cost-effectiveness of infliximab for severe treatment resistant rheumatoid arthritis in the UK The cost-effectiveness of infliximab for severe treatment resistant rheumatoid arthritis in the UK Barbieri M, Wong J B, Drummond M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of infliximab (INF) plus methotrexate (MTX) for the treatment of patients with rheumatoid arthritis (RA). INF (Remicade) is a new anti-tumour necrosis factor-alpha therapy that has recently been approved for the treatment of severe treatment-resistant RA. The dosages of INF used were 3 or 10 mg/kg for 4 or 8 weeks. Type of intervention

NHS Economic Evaluation Database.2005

139. Infliximab for induction and maintenance therapy for ulcerative colitis.

Infliximab for induction and maintenance therapy for ulcerative colitis. 16339095 2005 12 12 2005 12 20 2015 11 19 1533-4406 353 23 2005 Dec 08 The New England journal of medicine N. Engl. J. Med. Infliximab for induction and maintenance therapy for ulcerative colitis. 2462-76 Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. Two randomized, double-blind, placebo-controlled studies (...) --the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively)--evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ulcerative colitis despite treatment with concurrent medications received placebo or infliximab (5 mg or 10 mg per kilogram of body weight) intravenously at weeks 0, 2, and 6 and then every eight weeks through week 46 (in ACT 1) or week 22 (in ACT 2). Patients

NEJM2005

140. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade)

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade) The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade) The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade) Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of infliximab, 5 mg/kg every 6 weeks with a loading infusion after 2 weeks, in the treatment of ankylosing spondylitis (AS). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients suffering from AS. Setting

NHS Economic Evaluation Database.2004